Investigating Two rTMS Strategies to Treat Cannabis Use Disorder
A Preliminary Investigation of Two Repetitive Transcranial Magnetic Stimulation (rTMS) Strategies to Treat Cannabis Use Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Study Team
- Phone Number: (650) 800-6920
- Email: brainstimulationstudy@stanford.edu
Study Contact Backup
- Name: Gregory Sahlem
- Email: gsahlem@stanford.edu
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
- Participants must be between the ages of 18 and 60.
- Participants must meet DSM-5 criteria for at least moderate Cannabis Use Disorder, with use of at least 20 out of the last 28 days.
- Participants must express a desire to reduce cannabis use or quit.
- Participants must have a positive UDS for cannabis during their enrollment visit (confirming they are regular users).
- The investigative team must believe each participant is a good study-candidate.
Exclusion Criteria:
- Participants must not be pregnant or breastfeeding.
- Participants must not meet moderate or severe use disorder of any other substance with the exception of tobacco/nicotine.
- Participants must not be on any medications that have central nervous system effects that have changed in the past 4-weeks.
- Participants must not have a history of/or current psychotic disorder or bipolar disorder.
- Participants must not have any other Axis I condition requiring current treatment.
- Participants must not have a history of Dementia or other cognitive impairment.
- Participants must not have active suicidal ideation, or a suicide attempt within the past 180 days.
- Participants must not have any contraindications to receiving rTMS or MRI (e.g. metal implanted above the head, history of seizure, any known brain lesion).
- Participants must not have any unstable general medical conditions.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dorsolateral Prefrontal Cortex (DLPFC)
36 sessions of high frequency (10Hz) rTMS
|
Patterned pulsed magnetic stimulation delivered using an electromagnet.
We will use a MagVenture rTMS device and a Cool-B65 coil.
|
|
Experimental: Ventromedial Prefrontal Cortex (vmPFC)
36 sessions of low frequency (1Hz) rTMS
|
Patterned pulsed magnetic stimulation delivered using an electromagnet.
We will use a MagVenture rTMS device and a Cool-B65 coil.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number (%) of Participants Who Started and Completed Treatment
Time Frame: 6 to 9 weeks
|
6 to 9 weeks
|
|
|
Number (%) of Participants Who Had Successful Generation of Functional Magnetic Resonance Imaging (fMRI) Targets
Time Frame: Day 1 (90 minutes to complete scan)
|
Day 1 (90 minutes to complete scan)
|
|
|
Number (%) Weeks of Abstinence From Cannabis
Time Frame: 13 weeks (final 7 weeks of active treatment plus 6-week post-treatment follow-up)
|
Number (%) of weeks where the participant does not use any cannabis.
|
13 weeks (final 7 weeks of active treatment plus 6-week post-treatment follow-up)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Days of Use Per Week.
Time Frame: 4 weeks prior to baseline assessment and 7 weeks at the end of treatment through 6-week post-treatment follow-up
|
Number of days per week (0-7) where the participant uses any cannabis.
At the time of enrollment participants were asked to recall the number of days of cannabis use per week for the 4 weeks prior to enrollment.
Participants were then asked (over a period of 7 weeks) to recall days of use at the last fMRI visit (during prior week) and at the week 2, 4, and 6 follow-up visits.
Average values are reported for the 4-week period prior to enrollment and the 7-week period at end of treatment at follow-up.
|
4 weeks prior to baseline assessment and 7 weeks at the end of treatment through 6-week post-treatment follow-up
|
|
Average Number of Use Sessions Per Week.
Time Frame: 4 weeks prior to baseline assessment and 7 weeks at the end of treatment through 6-week post-treatment follow-up
|
Number of use sessions per week where the participant uses any cannabis.
At the time of enrollment participants were asked to recall the number of cannabis use sessions per week for the 4 weeks prior to enrollment.
Participants were then asked (over a period of 7 weeks) to recall the number of cannabis use sessions at the last fMRI visit (during prior week) and at the week 2, 4, and 6 follow-up visits.
Average values are reported for the 4-week period prior to enrollment and the 7-week period at end of treatment at follow-up.
|
4 weeks prior to baseline assessment and 7 weeks at the end of treatment through 6-week post-treatment follow-up
|
|
Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) Scale Score
Time Frame: Baseline and end of the follow-up period (12 to 15 weeks post-baseline)
|
The Q-LES-Q-SF overall score range is from 14 to 70, with higher scores indicating greater satisfaction and enjoyment.
The total score is expressed as a percentage of the maximum possible score (1-100).
|
Baseline and end of the follow-up period (12 to 15 weeks post-baseline)
|
|
Number of Participants Who Had a Period of 4-consecutive Weeks of Abstinence During the Follow-up Period
Time Frame: Follow-up period (final week of active treatment plus 6-week post-treatment follow-up)
|
Based on patient self-report of any 4-week period of abstinence
|
Follow-up period (final week of active treatment plus 6-week post-treatment follow-up)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gregory Sahlem, Stanford University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 68235
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.